The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

Adcetris Improves ORR4 in Phase III Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Takeda Pharmaceutical Co. Ltd. and Seattle Genetics Inc. said that the phase III ALCANZA clinical trial evaluating Adcetris (brentuximab vedotin) in cutaneous T-cell lymphoma met its primary endpoint, demonstrating a highly statistically significant improvement in the rate of objective response lasting at least four months (ORR4).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Clinical Roundup

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds

A study led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found the drug pirtobrutinib worked as well as another drug, ibrutinib, in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, and people in the study responded better with pirtobrutinib.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account